ProPhase Labs, Inc. (PRPH)
Stock Price:
$1.79 USD
-0.09 (-4.79%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
20.75M |
| Revenue (ttm) |
9.45M |
| Net Income (ttm) |
-2.94M |
| Shares Out |
11.59M |
| EPS (ttm) |
-0.25 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$1.79 |
| Previous Close |
$1.88 |
| Change ($) |
-0.09 |
| Change (%) |
-4.79% |
| Day's Open |
1.82 |
| Day's Range |
1.75 - 1.89 |
| Day's Volume |
1,044 |
| 52-Week Range |
1.20 - 2.59 |
More Stats
| Market Cap |
20.75M |
| Enterprise Value |
19.21M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
11.59M |
| Float |
8.78M |
| EPS (basic) |
-0.26 |
| EPS (diluted) |
-0.25 |
| FCF / Share |
-0.20 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
253 |
| Short Ratio |
0.02 |
| Short % of Float |
n/a |
| Beta |
-0.08 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
2.20 |
| PB Ratio |
1.83 |
| Revenue |
9.45M |
| Operating Income |
-3.01M |
| Net Income |
-2.94M |
| Free Cash Flow |
-2.26M |
| Net Cash |
1.54M |
| Net Cash / Share |
0.13 |
| Gross Margin |
27.68% |
| Operating Margin |
-31.83% |
| Profit Margin |
-31.10% |
| FCF Margin |
-23.87% |
| ROA |
-13.22% |
| ROE |
-22.04% |
| ROIC |
-24.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
8.00
Current: $1.79
High
8.00
Target: 8.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 9.88 | 13.13 | 9.87 | 4.21 | 2.52 | 22.07 | 25.03 | 22.41 | 17.45 | 14.50 |
| Revenue Growth | -24.76% | 33.03% | 134.59% | 67.04% | -88.59% | -11.83% | 11.72% | 28.38% | 20.35% | - |
| Gross Profit | 2.62 | 4.78 | 1.95 | 1.00 | 0.83 | 14.18 | 16.67 | 14.25 | 11.28 | 8.83 |
| Operating Income | -3.24 | -1.63 | -3.99 | -3.79 | -2.08 | -7.83 | 0.42 | -1.10 | -2.74 | -3.59 |
| Net Income | -3.15 | -1.74 | 40.59 | -2.87 | -3.60 | -7.83 | 0.41 | -1.09 | -2.71 | -3.50 |
| Shares Outstanding | 11.56 | 11.40 | 15.57 | 17.08 | 16.40 | 16.77 | 15.84 | 14.84 | 14.82 | 14.29 |
| Earnings Per Share | -0.27 | -0.15 | 2.59 | -0.17 | -0.22 | -0.47 | 0.03 | -0.07 | -0.18 | -0.25 |
| Dividend Per Share | 0.50 | 1.00 | - | - | - | - | - | - | - | - |
| Dividend Growth | -50% | - | - | - | - | - | - | - | - | - |
| Operating Cash Flow | -0.84 | -2.12 | -2.84 | -0.47 | -3.50 | -3.22 | 1.14 | -5.73 | -2.11 | -3.55 |
| Capital Expenditures | -0.23 | -0.14 | 40.62 | -0.65 | -0.72 | -0.31 | -0.44 | -0.31 | -0.13 | -0.15 |
| Free Cash Flow | -1.07 | -2.26 | 37.78 | -1.12 | -4.22 | -3.52 | 0.70 | -6.04 | -2.24 | -3.70 |
| Cash & Equivalents | 1.36 | 8.24 | 21.94 | 0.44 | 1.66 | 2.93 | 1.64 | 0.57 | 5.54 | 8.23 |
| Total Debt | - | - | - | 1.49 | 1.47 | - | - | - | - | - |
| Net Cash / Debt | 1.36 | 8.24 | 21.94 | -1.05 | 0.20 | 2.93 | 1.64 | 0.57 | 5.54 | 8.23 |
| Assets | 12.27 | 20.74 | 33.66 | 12.80 | 14.83 | 16.06 | 17.42 | 16.66 | 19.08 | 21.70 |
| Liabilities | 1.04 | 4.23 | 1.81 | 6.84 | 6.00 | 5.34 | 4.82 | 5.21 | 7.85 | 8.24 |
| Book Value | 11.23 | 16.50 | 31.85 | 5.96 | 8.83 | 10.72 | 12.60 | 11.45 | 11.23 | 13.46 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
ProPhase Labs, Inc. |
| Country |
United States |
| Employees |
48 |
| CEO |
Ted William Karkus |
Stock Information
| Ticker Symbol |
PRPH |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NASDAQ: PRPH |
| IPO Date |
January 16, 1997 |
Description
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter(OTC) consumer healthcare products, dietary supplements, and other remedies in the United States. The company offers TK Supplements product line, including Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support; and Super ProstaFlow+ a supplement to support prostate and urinary health. In addition, the company provides contract manufacturing services for OTC healthcare and dietary supplements products. It markets its products through national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Doylestown, Pennsylvania.